These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1585076)

  • 1. Effect of glipizide on serum insulin and glucose concentrations in healthy cats.
    Miller AB; Nelson RW; Kirk CA; Neal L; Feldman EC
    Res Vet Sci; 1992 Mar; 52(2):177-81. PubMed ID: 1585076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats.
    Bennett N; Papich MG; Hoenig M; Fettman MJ; Lappin MR
    Am J Vet Res; 2005 Apr; 66(4):581-8. PubMed ID: 15900936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an orally administered sulfonylurea, glipizide, for treatment of diabetes mellitus in cats.
    Nelson RW; Feldman EC; Ford SL; Roemer OP
    J Am Vet Med Assoc; 1993 Sep; 203(6):821-7. PubMed ID: 8226235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
    Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
    Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of hyperglycemia after oral glucose load by the new alpha 2-adrenergic receptor antagonist SL 84.0418 in healthy subjects.
    Berlin I; Rosenzweig P; Chalon S; Fuseau E; Landault C; Cesselin F; Blacker C; Puech AJ
    Clin Pharmacol Ther; 1994 Mar; 55(3):338-45. PubMed ID: 7908257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus.
    Jaber LA; Ducharme MP; Halapy H
    Ther Drug Monit; 1996 Feb; 18(1):6-13. PubMed ID: 8848822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The acute effect of preprandial exogenous and endogenous sulphonylurea-stimulated insulin secretion on postprandial glucose excursions in patients with type 2 diabetes.
    Groop PH; Melander A; Groop LC
    Diabet Med; 1993; 10(7):633-7. PubMed ID: 8403824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient clinical diabetes mellitus in cats: 10 cases (1989-1991).
    Nelson RW; Griffey SM; Feldman EC; Ford SL
    J Vet Intern Med; 1999; 13(1):28-35. PubMed ID: 10052060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIDDM in the cat: treatment with the oral hypoglycemic medication, glipizide.
    Ford SL
    Vet Clin North Am Small Anim Pract; 1995 May; 25(3):599-615. PubMed ID: 7660535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental study of glipizide. A comparison with other hypoglycemic sulfonamides (author's transl)].
    Loubatières AL; Loubatieres-Mariani MM; Alric R; Ribes G; Sorial G; Tarasco A
    Diabete Metab; 1975 Mar; 1():13-21. PubMed ID: 824163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitrochalcones: potential in vivo insulin secretagogues.
    Damazio RG; Zanatta AP; Cazarolli LH; Mascarello A; Chiaradia LD; Nunes RJ; Yunes RA; Silva FR
    Biochimie; 2009; 91(11-12):1493-8. PubMed ID: 19747522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus.
    Feldman EC; Nelson RW; Feldman MS
    J Am Vet Med Assoc; 1997 Mar; 210(6):772-7. PubMed ID: 9074678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forearm insulin uptake in healthy subjects after oral glucose and intravenous glipizide.
    Nygren A; Lindblad LE; Sundblad L
    Acta Endocrinol (Copenh); 1981 Nov; 98(3):407-12. PubMed ID: 7027714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM.
    Pasmantier R; Chaiken RL; Hirsch SR; Lebovitz HE
    Diabetes Care; 1990 Aug; 13 Suppl 3():42-6. PubMed ID: 2209343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.
    Abbasi F; Kamath V; Rizvi AA; Carantoni M; Chen YD; Reaven GM
    Diabetes Care; 1997 Dec; 20(12):1863-9. PubMed ID: 9405908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice.
    Manohar V; Talpur NA; Echard BW; Lieberman S; Preuss HG
    Diabetes Obes Metab; 2002 Jan; 4(1):43-8. PubMed ID: 11874441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glipizide treatment on response to an infused glucose load in patients with NIDDM.
    Sheu WH; Jeng CY; Fuh MM; Chen YD; Reaven GM
    Diabetes Care; 1995 Dec; 18(12):1582-7. PubMed ID: 8722055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosylated hemoglobin concentration for assessment of glycemic control in diabetic cats.
    Elliott DA; Nelson RW; Feldman EC; Neal LA
    J Vet Intern Med; 1997; 11(3):161-5. PubMed ID: 9183767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of glipizide and its effect on blood glucose and insulin levels in patients with non-insulin-dependent diabetes.
    Peterson CM; Sims RV; Jones RL; Rieders F
    Diabetes Care; 1982; 5(5):497-500. PubMed ID: 6765225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.